GE HealthCare Technologies Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy GEHC?
Source: seekingalpha
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GE HealthCare Reports Strong Earnings, Stock Surges
- Strong Earnings Report: GE HealthCare reported adjusted earnings of $1.44 per share, surpassing the consensus estimate of $1.40, which reflects the company's robust performance in the healthcare solutions sector and boosts investor confidence.
- Sales Growth: The company achieved sales of $5.69 billion, exceeding expectations of $5.61 billion, with an overall growth of 7.1%, driven by Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions, indicating strong market demand in the U.S. and EMEA regions.
- Order Metrics: Total orders increased organically by 2%, with a book-to-bill ratio of 1.06, demonstrating the company's competitive position and future growth potential, as CEO Arduini highlighted healthy capital investment trends and demand for new products.
- Future Outlook: GE HealthCare forecasts adjusted earnings for 2026 to be between $4.95 and $5.15 per share, exceeding the consensus of $4.92, showcasing the company's confidence in delivering profitable growth and strong cash flow amid a dynamic macro environment.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
GE HealthCare Surpasses Expectations with 2026 Outlook
- Earnings Beat: GE HealthCare reported $5.7 billion in Q4 2025 revenue, achieving approximately 7% year-over-year growth that exceeded consensus estimates by $100 million, showcasing strong performance in the U.S. and EMEA markets, which bolsters investor confidence.
- Segment Performance: The Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions segments contributed $790 million, $2.6 billion, and $1.5 billion in revenue, with year-over-year growth rates of approximately 22%, 7%, and 6%, respectively, indicating robust growth potential across multiple business areas.
- Profitability Shift: Although the adjusted EBIT margin slipped 200 basis points to 16.7% compared to the prior year, the adjusted EPS of $1.44 beat expectations by $0.04, demonstrating the company's ability to maintain profitability amid tariff-related challenges.
- 2026 Outlook: GE HealthCare projects an adjusted EPS of $4.59 and revenue of $20.6 billion for 2026, reflecting approximately 5% and 2% year-over-year growth, respectively, with an expected adjusted EPS range of $4.95 to $5.15, indicating a cautiously optimistic outlook for the future.
See More
GE HealthCare Technologies Q4 Earnings Exceed Expectations
- Earnings Beat: GE HealthCare Technologies reported a Q4 Non-GAAP EPS of $1.44, exceeding expectations by $0.04, indicating robust performance in the medical equipment sector and boosting market confidence in future growth.
- Revenue Growth: The company achieved revenue of $5.7 billion, a 7.1% year-over-year increase that surpassed market expectations by $100 million, primarily driven by strong demand in the U.S. and Europe, the Middle East, and Africa, further solidifying its market position.
- Cash Flow Performance: Operating cash flow reached $1.0 billion with free cash flow at $916 million, demonstrating strong financial management and profitability, which supports future investments and shareholder returns.
- 2026 Guidance: The company projects organic revenue growth of 3.0% to 4.0% for 2026, with adjusted EPS expected to be between $4.95 and $5.15, reflecting an optimistic outlook for future performance despite market challenges.
See More
GE HealthCare Shares Climb Following Positive Earnings Report.
- Stock Performance: GE HealthCare Technologies’ stock experienced an increase early Wednesday following the release of its quarterly results.
- Financial Outlook: The company provided a positive outlook for the upcoming year, contributing to investor confidence.
See More
GE HealthCare Exceeds 2025 Revenue and EPS Expectations
- Significant Revenue Growth: In Q4 2025, GE HealthCare reported revenues of $5.7 billion, marking a 7.1% increase year-over-year, with organic revenue growth of 4.8%, primarily driven by strong performance in the U.S. and EMEA regions, indicating robust market demand.
- Profitability Improvement: The company achieved a net income of $589 million in Q4, with a net income margin of 10.3%, and despite tariff impacts, the adjusted EBIT margin remained at 16.7%, showcasing operational resilience and effective cost management.
- Strong Cash Flow Performance: For the full year 2025, cash flow from operating activities reached $2.0 billion, with free cash flow at $1.5 billion; although free cash flow saw a slight decline, the cash flow conversion rate was an impressive 95%, reflecting solid financial health.
- Optimistic 2026 Outlook: The company anticipates organic revenue growth of 3% to 4% for 2026, with adjusted EPS guidance set between $4.95 and $5.15, demonstrating confidence in future growth driven by innovation and market demand.
See More
GE HealthCare Reports Strong Earnings, Stock Surges
- Strong Earnings Report: GE HealthCare reported adjusted earnings of $1.44 per share, surpassing the consensus estimate of $1.40, which reflects the company's robust performance in the healthcare solutions sector and boosts investor confidence.
- Sales Growth: The company achieved sales of $5.69 billion, exceeding expectations of $5.61 billion, with an overall growth of 7.1%, driven by Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions, indicating strong market demand in the U.S. and EMEA regions.
- Order Metrics: Total orders increased organically by 2%, with a book-to-bill ratio of 1.06, demonstrating the company's competitive position and future growth potential, as CEO Arduini highlighted healthy capital investment trends and demand for new products.
- Future Outlook: GE HealthCare forecasts adjusted earnings for 2026 to be between $4.95 and $5.15 per share, exceeding the consensus of $4.92, showcasing the company's confidence in delivering profitable growth and strong cash flow amid a dynamic macro environment.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
GE HealthCare Surpasses Expectations with 2026 Outlook
- Earnings Beat: GE HealthCare reported $5.7 billion in Q4 2025 revenue, achieving approximately 7% year-over-year growth that exceeded consensus estimates by $100 million, showcasing strong performance in the U.S. and EMEA markets, which bolsters investor confidence.
- Segment Performance: The Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions segments contributed $790 million, $2.6 billion, and $1.5 billion in revenue, with year-over-year growth rates of approximately 22%, 7%, and 6%, respectively, indicating robust growth potential across multiple business areas.
- Profitability Shift: Although the adjusted EBIT margin slipped 200 basis points to 16.7% compared to the prior year, the adjusted EPS of $1.44 beat expectations by $0.04, demonstrating the company's ability to maintain profitability amid tariff-related challenges.
- 2026 Outlook: GE HealthCare projects an adjusted EPS of $4.59 and revenue of $20.6 billion for 2026, reflecting approximately 5% and 2% year-over-year growth, respectively, with an expected adjusted EPS range of $4.95 to $5.15, indicating a cautiously optimistic outlook for the future.
See More
GE HealthCare Technologies Q4 Earnings Exceed Expectations
- Earnings Beat: GE HealthCare Technologies reported a Q4 Non-GAAP EPS of $1.44, exceeding expectations by $0.04, indicating robust performance in the medical equipment sector and boosting market confidence in future growth.
- Revenue Growth: The company achieved revenue of $5.7 billion, a 7.1% year-over-year increase that surpassed market expectations by $100 million, primarily driven by strong demand in the U.S. and Europe, the Middle East, and Africa, further solidifying its market position.
- Cash Flow Performance: Operating cash flow reached $1.0 billion with free cash flow at $916 million, demonstrating strong financial management and profitability, which supports future investments and shareholder returns.
- 2026 Guidance: The company projects organic revenue growth of 3.0% to 4.0% for 2026, with adjusted EPS expected to be between $4.95 and $5.15, reflecting an optimistic outlook for future performance despite market challenges.
See More
GE HealthCare Shares Climb Following Positive Earnings Report.
- Stock Performance: GE HealthCare Technologies’ stock experienced an increase early Wednesday following the release of its quarterly results.
- Financial Outlook: The company provided a positive outlook for the upcoming year, contributing to investor confidence.
See More
GE HealthCare Exceeds 2025 Revenue and EPS Expectations
- Significant Revenue Growth: In Q4 2025, GE HealthCare reported revenues of $5.7 billion, marking a 7.1% increase year-over-year, with organic revenue growth of 4.8%, primarily driven by strong performance in the U.S. and EMEA regions, indicating robust market demand.
- Profitability Improvement: The company achieved a net income of $589 million in Q4, with a net income margin of 10.3%, and despite tariff impacts, the adjusted EBIT margin remained at 16.7%, showcasing operational resilience and effective cost management.
- Strong Cash Flow Performance: For the full year 2025, cash flow from operating activities reached $2.0 billion, with free cash flow at $1.5 billion; although free cash flow saw a slight decline, the cash flow conversion rate was an impressive 95%, reflecting solid financial health.
- Optimistic 2026 Outlook: The company anticipates organic revenue growth of 3% to 4% for 2026, with adjusted EPS guidance set between $4.95 and $5.15, demonstrating confidence in future growth driven by innovation and market demand.
See More
